236 
Market Cap
Stock Chart
Starpharma - 30 day Poll
Recent BLOGS About Starpharma Add New
Latest Company News
|
Movers and shakers
Australian Life Scientist - May 8, 2012 TGA national manager; Hatchtech's new CEO; Starpharma's new director; Immuron CEO; University of Queensland vice chancellor and president.
|
|
Midday: Aus shares pare gains
Finance News Network (press release) (subscription) - Apr 27, 2012 The Australian share market opened 0.3 per cent higher on the back of positive leads from Wall Street but has pared gains and dipped into the red at noon.
|
|
Starpharma Holdings Limited Announces Advancement Of Drug Delivery Collaboration
Reuters Key Development - Dec 18, 2011 |
|
Starpharma Holdings Limited Completes AUD 32 Million Placement
Reuters Key Development - Nov 15, 2011 |
|
Starpharma Holdings Limited Not To Pay FY 2011 Final Dividend
Reuters Key Development - Aug 29, 2011 |
Website
Videos related to Starpharma
Company Profile
Cash Balance & Finances
Starpharma reported negative cash flow of approx. $1.8m for quarter ended 31 Dec 2011.
Cash in hand at the end of the quarter was approx. $49m.
ASX and OTCQX listed
Commercial relationships include: Dade Behring (Siemens), SSL (Durex condoms), Elanco (Eli Lilly), EMD Merck, Sigma Aldrich, Stiefel Inc., Qiagen
Largest shareholders include: Dow Chemical Co., Acorn, Platinum LLC; ~22% US shareholding
Starpharma Holdings Limited is an Australia-based company engaged in the development and commercialization of dendrimer products for pharmaceutical, life-science and other applications. Activities within the Company are directed towards the development of nano-scale materials, with a particular focus on the development of its topical vaginal microbicide, VivaGel, for the prevention of genital herpes and human immunodeficiency virus (HIV), and the application of dendrimers to drug delivery and other life science applications.
It is also engaged in exploring dendrimer opportunities in materials science with applications in areas, such as adhesives, lubricants and water remediation. The activities are managed by the Company’s wholly owned subsidiaries Starpharma Pty Ltd. in Melbourne and Australia, and Dendritic Nanotechnologies (DNT), Inc. in Michigan, United States.
The company predicts the world’s first herpes-killing vaginal gel may go on sale by 2012 and they plan to start patient studies on its effectiveness for genital herpes in 2010-11. Chief Executive Officer Jackie Fairley said in an interview in Singapore, declining to identify the partners. The Melbourne-based company licensed its VivaGel- coated condoms in 2008 to SSL International Plc, maker of the world’s best-selling Durex brand.